Introduction to Drug Hunting

О курсе

This course introduces and summarizes the different steps of preclinical drug discovery, wrapping up with a brief description of the subsequent clinical trials and the importance of competitive intelligence in project strategy.  It provides a high-level overview for those interested in a more general understanding of the topic and forms the foundation for a more in-depth exploration of topics covered in other courses in this series. Target audience: This course is suitable for life scientists, clinicians, and individuals from fields that support drug discovery (e.g., patents, finance, licensing, etc.) interested in learning more about the pharmaceutical/biotechnology sector. Advanced undergraduate coursework or practical familiarity/working knowledge in biological sciences and organic chemistry is recommended.

Навыки, которые вы освоите

Учитесь у экспертов

Erland Stevens, PhD

James G. Martin Professor of Chemistry, Davidson College

W. Ross Tracey, PhD

Associate Director, Biomedical Research Learning, Novartis

Douglas S. Auld, PhD

Associate Director, Discovery Sciences, Biomedical Research, Novartis

Alan P. Brown, PhD, DABT

Director, Preclinical Safety, Biomedical Research, Novartis

Sujal Deshmukh, PhD

Director, Pharmacokinetic Sciences, Biomedical Research, Novartis

Stephanie Dodd, MSc.

Associate Director, Chemical & Pharmaceutical Profiling, Development, Novartis

Sabine Guth, PhD

Director, Diseases Of Aging and Regenerative Medicine, Biomedical Research, Novartis

Thomas M. Smith, PhD

Associate Director, Early Strategic Partnerships Biomedical Research, Novartis